

GSK's Synflorix and Non-typeable *Haemophilus influenzae* (NTHi): the secret to beating Wyeth?

LONDON, UK----2nd April 2009----ExpertREACT. The recent EU approval and ongoing development of GSK Biological's new *pneumococcal* vaccine Synflorix point towards Non-typeable *Haemophilus influenzae* (NTHi) becoming an increasingly significant target for vaccine development. Within recent research, **VacZine Analytics** discusses current competitive drivers behind the selection of the pathogen, particularly considerations within acute otitis media (AOM) and pneumonia. Overtime, Wyeth could have a potential weakness.

*****NOTE***** This article is available only on a "pay per view" basis or to individual existing **VacZine Analytics** clients who have purchased **DiseaseINFOPACK** Non-typeable *Haemophilus influenzae* (CAT No: VADIP011), published March 2009.

Please visit www.vaczone-analytics/products-expertreact

References:

- 1) Sethi S, Murphy TF :Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001, 14(2):336-363
- 2) Barbosa-Cesnik C et al. Predictors for *Haemophilus influenzae* colonization, antibiotic resistance and for sharing an identical isolate among children attending 16 licensed day-care centers in Michigan. Pediatr Infect Dis J. 2006 Mar;25(3):219-23
- 3) Number of People with Care for Selected Conditions by Type of Service: United States, 2006. Agency for Healthcare Research and Quality, Rockville. Available at: <http://www.meps.ahrq.gov/>. Accessed: 5 March 2009
- 4) Casey JR & Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004 Sep;23(9):824-8
- 5) **DiseaseINFOPACK**. Non-typeable *haemophilus influenzae* (CAT No: VADIP011), published by **VacZine Analytics**, March 2009.
- 6) Eskola J et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001 Feb 8;344(6):403-9
- 7) Sox CM et al. Trends in otitis media treatment failure and relapse. Pediatrics. 2008 Apr;121(4):674-9.
- 8) GSK Corporate Press Release, 31st March 2009. Available at: <http://www.gsk.com>. Accessed April 2009.

For more information about VacZine Analytics products and services please visit www.vaczone-analytics.com

About VacZine Analytics:

VacZine Analytics is a new strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new



